Veradermics (NYSE:MANE) Stock Gets Price Target Boost from Citigroup

Veradermics (NYSE:MANE – Get Free Report) had its price target upped by Citigroup from $160.00 to $175.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price objective would suggest a potential upside of 12.10% from the stock’s current price.

MANE has been the subject of a number of other research reports. Needham & Company LLC increased their price objective on Veradermics from $164.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Wall Street Zen raised shares of Veradermics from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Veradermics in a report on Monday, October 19th. B. Riley Financial increased their price target on shares of Veradermics from $170.00 to $204.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Finally, UBS Group set a $204.00 price target on shares of Veradermics in a report on Thursday, October 22nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Veradermics currently has an average rating of “Moderate Buy” and a consensus target price of $174.57.

Get Our Latest Stock Analysis on Veradermics

Veradermics Stock Performance

Shares of MANE stock opened at $156.11 on Tuesday. Veradermics has a 1-year low of $32.00 and a 1-year high of $156.63. The business has a 50-day moving average of $120.82 and a 200 day moving average of $98.02.

Veradermics (NYSE:MANE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. As a group, equities analysts anticipate that Veradermics will post -2.87 EPS for the current year.

Insider Buying and Selling at Veradermics

In other news, CEO Reid Alexander Waldman sold 67,500 shares of Veradermics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.86, for a total value of $7,280,550.00. Following the sale, the chief executive officer directly owned 170,824 shares in the company, valued at approximately $18,425,076.64. This trade represents a 28.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Timothy August Durso sold 43,500 shares of Veradermics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.82, for a total value of $4,690,170.00. Following the completion of the sale, the insider owned 78,142 shares in the company, valued at approximately $8,425,270.44. This represents a 35.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 861,000 shares of company stock valued at $92,408,220 in the last 90 days.

Hedge Funds Weigh In On Veradermics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nvwm LLC lifted its stake in Veradermics by 105.4% in the third quarter. Nvwm LLC now owns 228 shares of the company’s stock worth $28,000 after acquiring an additional 117 shares during the period. Sterling Capital Management LLC increased its position in Veradermics by 233.2% during the 3rd quarter. Sterling Capital Management LLC now owns 633 shares of the company’s stock valued at $77,000 after purchasing an additional 443 shares during the period. Russell Investments Group Ltd. increased its position in Veradermics by 8.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,905 shares of the company’s stock valued at $231,000 after purchasing an additional 147 shares during the period. Private Wealth Asset Management LLC purchased a new position in Veradermics during the 3rd quarter valued at $249,000. Finally, Pictet Asset Management Holding SA raised its holdings in Veradermics by 22.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 2,491 shares of the company’s stock worth $302,000 after purchasing an additional 449 shares in the last quarter.

Key Veradermics News

Here’s some of the latest news about MANE:

  • Positive Sentiment: Veradermics reported positive results from the 12-month Study 302 Part B evaluation of VDPHL01, its potential treatment for pattern hair loss. The clinical update appears to be a key catalyst, though the reports provided here do not include detailed efficacy figures. Veradermics stock rises on 12-month hair growth trial data Study 302 Part B results transcript
  • Positive Sentiment: Third-quarter EPS was a loss of $0.50, but that was better than analysts’ expected loss of $0.59. The company also highlighted recent corporate and clinical progress. Third-quarter 2026 results and progress
  • Negative Sentiment: Despite beating the estimate, Veradermics remained loss-making in the quarter, so investors will likely focus on clinical execution and the path toward commercialization. Q3 earnings snapshot

Veradermics Company Profile

(Get Free Report)

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

Read More

Analyst Recommendations for Veradermics (NYSE:MANE)

Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.